Hook 'em

University of Texas ranks as one of the world's most innovative schools

The University of Texas System scooted up three spots from 2017. University of Texas at Austin/Facebook

A new ranking from Reuters has placed the University of Texas System among the world's most innovative universities.

According to an October 11 release, the Reuters Top 100: The World's Most Innovative Universities "identifies and ranks the educational institutions doing the most to advance science, invent new technologies and power new markets and industries." The UT System ranked No. 6 out of the 100 best in the world. The 2018 ranking is a jump up from its No. 9 spot in 2017.

In addition to the flagship University of Texas at Austin, the system is comprised of seven other public universities across the state as well as six health institutions. Reuters notes that because of how the UT System reports on innovation, it assessed the entire enterprise rather than individual universities.

As a whole, the UT System boasts an impressive number of accolades that helped it scoot up three spots. As Reuters notes, chief among these accolades is the National Science Foundation's $60 million grant to the Texas Advanced Computing Center at the University of Texas at Austin to build a supercomputer and the system's $2.7 billion in annual research expenditures. (Not to mention numerous Nobel Laureates among both faculty and alumni.)

Overall, the U.S. dominated the list, claiming 46 out of the 100 spots. Rounding out the top 10 for 2018 is: No. 1, Stanford University; No. 2, Massachusetts Institute of Technology; No. 3, Harvard University; No. 4, University of Pennsylvania; No. 5, University of Washington; No. 7, Belgium's KU Leuven, No. 8, U.K.'s Imperial College London; No. 9, University of North Carolina at Chapel Hill; and No. 10, Vanderbilt University.

---

This story originally appeared on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted